| | Over a decade in the making, CAR T-Cell Therapy has proven to be one of the more innovative and promising treatments in oncology. Learn more about what companies should consider when it comes to this cutting edge treatment from a free white paper by TD2. |
Merck, via its Themis buy, to move first COVID-19 vaccine into clinical development in Q3 J&J COVID-19 vaccine candidate protects monkeys after single dose Cerevel to raise $445M, hit Wall Street via blank check company Sponsored: FROM CHOLERA TO COVID-19: How integrated data visualizations inform decisions and impact actions BioNTech, Regeneron join forces in I-O battle against melanoma AlloVir raises $276M IPO to run broad cell therapy program Bristol Myers, bluebird refile for CAR-T approval after FDA rejection U.K. antibody test approved to support government's free coronavirus screening efforts Top vaccine players Sanofi, GSK win $2.1B Warp Speed funding for COVID-19 shot FiercePharmaAsia—Daiichi's win-lose week; Astra's China business; Novavax-Fujifilm COVID-19 vax deal Chutes & Ladders—Nura Bio uncloaks with Seth at the helm Featured Story | By Ben Adams Merck was purposely cautious during the start of the pandemic when it came to vaccine development but is now slowly but surely ramping up its efforts into the clinic. read more |
| |
|---|
|
Top Stories By Arlene Weintraub Scientists led by Beth Israel Deaconess Medical Center in Boston tested seven different COVID-19 vaccine candidates from J&J in nonhuman primates, landing on one that prevented the virus from infecting the animals' lungs with a single dose. The company plans to test both a one- and two-dose regimen in clinical trials. read more By Amirah Al Idrus Unlike a traditional biotech built around a lab discovery, Cerevel Therapeutics got a “unique” start: with $350 million from Bain Capital and a clutch of central nervous system programs from Pfizer. Now, it’s continuing its unorthodox streak as it taps the public markets. read more By PerkinElmer, Inc How integrated data visualizations inform decisions and impact actions. Data visualization was first used to recognize disease patterns in the 1854 London cholera outbreak. It is even more essential today. read more By Amirah Al Idrus Checkpoint inhibitors can be lifesaving for some cancer patients, but in melanoma, at least half of patients don’t respond to drugs like Merck’s Keytruda and Bristol Myers Squibb’s Opdivo. And those who do often develop resistance to the drug. BioNTech and Regeneron are teaming up to help those patients. read more By Nick Paul Taylor AlloVir has raised $276 million in an upsized IPO to fund development of allogeneic T-cell treatments for viral diseases. The money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses. read more By Nick Paul Taylor Bristol Myers Squibb and bluebird bio have refiled for approval of anti-BCMA CAR-T therapy ide-cel. The action, which comes two months after the FDA hit the partners with a refuse to file letter, keeps Bristol Myers in with a shot of winning approval before a deadline set in its takeover of Celgene. read more By Conor Hale A coalition of U.K. research institutions and diagnostic developers backed by the British government has secured regulatory clearance to move ahead with their hand-held antibody blood test for COVID-19. read more By Angus Liu Sanofi, already working with BARDA on a GlaxoSmithKline-partnered COVID-19 vaccine, has won further support from the U.S. government—this time, to the tune of $2.1 billion for clinical development and delivery of 100 million doses. It's a hefty bet, but on a proven vaccine technology from two of the biggest vaccine makers in the business. read more By Angus Liu Daiichi Sankyo won a $1 billion upfront deal with AstraZeneca on an anti-TROP antibody-drug conjugate but lost a pediatric pentavalent vaccine collab with Sanofi. AstraZeneca's China business was hurt by a huge Pulmicort decline. Fujifilm will make Novavax's experimental COVID-19 vaccine. And more. read more By Kyle Blankenship Nura Bio has uncloaked with a $73 million financing round and Alpna Seth as CEO; Parexel taps Sanofi vet Joe as CMO; Parexel hires trio of regulatory vets. read more Resources Sponsored by: Lonza Pharma & Biotech A novel spray-dried dispersion platform has been developed to faciliate high drug load applications Sponsored by: PRA Health Sciences Collaboration across the industry will be key to meeting the demands of the RACE Act and ensuring pediatric patients receive the care and treatments they need. Sponsored by: Cambrex The industry trend of outsourcing to CDMOs continues. With more services, capabilities, facilities, and employees than ever before, our experts have contributed more articles to our biggest eBook yet. Sponsored by: EVERSANA How predictive analytics and machine learning have the potential to transform healthcare by predicting “Patient Switching Behaviors.” Sponsored by: Recro Gainesville Wurster processing is a versatile technique for developing and manufacturing multiparticulates for modified release dosage forms. Read this whitepaper to determine whether Wurster processing is the right option for your project. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. 18th Annual Discovery on Target Virtual September 16-18, 2020 Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now. | COVID19 provisions – training will be on-site as normal. | New – may be possible for some individuals to access the training virtually in real time. | 